Literature DB >> 30693889

Dental management prior to radiation therapy in patients with head and neck cancer.

Paula Bonar Alvarez1, Mario Perez-Sayáns2, Mônica Ghislaine Oliveira Alves3, Mercedes Gallas Torreira1, María Elena Padín Iruegas4, Andrés Blanco Carrión1, Abel García-García5.   

Abstract

INTRODUCTION: Patients diagnosed with head and neck tumors, are treated by surgery, radiation therapy (RT), chemotherapy (CT) or a combination thereof. The goal is to describe the management protocol for patients subjected to radiation therapy (RT) and to study their long-term oral health status.
MATERIALS AND METHODS: A retrospective study was performed in a sample of 50 patients. We analyzed the oral health status and all the variables included applying the adapted protocol of pre-RT.
RESULTS: Prior to RT, 84% of patients required scaling and 32% conservative treatment. Around 74% of patients required at least one exodontia. The mean of exodontias for patients presenting Grade 3 of oral hygiene was 6.50 per person (p<0.0001). The pre-RT study of possible candida infection showed that 78% of patients were negative for this infection. The mean resting saliva production was 39.10 (SD: 23.30; range: 13-145), with a stimulated value of 64.78 (SD: 33.92; range: 16-200).
CONCLUSIONS: All patients should be protocoled to ensure that they present optimal oral conditions prior to initiating RT treatment.

Entities:  

Keywords:  Head and neck tumors; oral health status; oral hygiene; radiotherapy; saliva

Mesh:

Year:  2018        PMID: 30693889     DOI: 10.4103/ijc.IJC_20_18

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  1 in total

1.  Effects of continuity of care on the postradiotherapy survival of working-age patients with oral cavity cancer: A nationwide population-based cohort study in Taiwan.

Authors:  Tsu Jen Kuo; Pei Chen Wu; Pei Ling Tang; Chun-Hao Yin; Chi Hsiang Chu; Yao-Min Hung
Journal:  PLoS One       Date:  2019-12-16       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.